PL337698A1 - Derivatives of 4-bromo- or iodo-phenylaminobenzhydroxamic acid and their application as mek inhibitors - Google Patents

Derivatives of 4-bromo- or iodo-phenylaminobenzhydroxamic acid and their application as mek inhibitors

Info

Publication number
PL337698A1
PL337698A1 PL98337698A PL33769898A PL337698A1 PL 337698 A1 PL337698 A1 PL 337698A1 PL 98337698 A PL98337698 A PL 98337698A PL 33769898 A PL33769898 A PL 33769898A PL 337698 A1 PL337698 A1 PL 337698A1
Authority
PL
Poland
Prior art keywords
iodo
bromo
derivatives
application
mek inhibitors
Prior art date
Application number
PL98337698A
Other languages
English (en)
Inventor
Stephen Douglas Barrett
Alexander James Bridges
Annette Marian Doherty
David Thomas Dudley
Alan Robert Saltiel
Haile Tecle
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PL337698A1 publication Critical patent/PL337698A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
PL98337698A 1997-07-01 1998-06-24 Derivatives of 4-bromo- or iodo-phenylaminobenzhydroxamic acid and their application as mek inhibitors PL337698A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5144097P 1997-07-01 1997-07-01
PCT/US1998/013106 WO1999001426A1 (en) 1997-07-01 1998-06-24 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors

Publications (1)

Publication Number Publication Date
PL337698A1 true PL337698A1 (en) 2000-08-28

Family

ID=21971339

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98337698A PL337698A1 (en) 1997-07-01 1998-06-24 Derivatives of 4-bromo- or iodo-phenylaminobenzhydroxamic acid and their application as mek inhibitors

Country Status (26)

Country Link
EP (1) EP0993439B1 (enExample)
JP (1) JP2002511092A (enExample)
KR (1) KR20010014362A (enExample)
CN (1) CN1163475C (enExample)
AR (1) AR016762A1 (enExample)
AT (1) ATE277895T1 (enExample)
AU (1) AU757046B2 (enExample)
BR (1) BR9810366A (enExample)
CA (1) CA2290506C (enExample)
CO (1) CO4940442A1 (enExample)
DE (1) DE69826662T2 (enExample)
ES (1) ES2229515T3 (enExample)
HR (1) HRP980368A2 (enExample)
HU (1) HUP0003731A3 (enExample)
IL (1) IL132840A (enExample)
IS (1) IS5256A (enExample)
MY (1) MY120994A (enExample)
NO (1) NO315271B1 (enExample)
NZ (1) NZ501276A (enExample)
PE (1) PE97999A1 (enExample)
PL (1) PL337698A1 (enExample)
PT (1) PT993439E (enExample)
TW (1) TW396149B (enExample)
UY (1) UY25076A1 (enExample)
WO (1) WO1999001426A1 (enExample)
ZA (1) ZA985728B (enExample)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
HUP0104607A3 (en) * 1998-12-15 2002-12-28 Warner Lambert Co Use of a mek inhibitor for preventing transplant rejection
EP1140067A1 (en) * 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
AP2001002225A0 (en) 1999-01-13 2001-09-30 Warner Lambert Co 1-heterocycle substituted diarylamines.
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
CA2348236A1 (en) * 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
ATE311363T1 (de) 1999-01-13 2005-12-15 Warner Lambert Co Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
EP1144371B1 (en) 1999-01-13 2005-11-09 Warner-Lambert Company Llc Benzenesulphonamide derivatives and their use as mek inhibitors
US6686499B1 (en) 1999-04-21 2004-02-03 Warner-Lambert Company Method for making 2-(N-phenylamino)benzoic acids
PL351085A1 (en) * 1999-04-21 2003-03-24 Warner Lambert Co Method for making 2-(n-phenylamino)benzoic acids
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
AU5786000A (en) * 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
BR0109188A (pt) * 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
US7001905B2 (en) 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
IL153817A0 (en) * 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
MXPA03001654A (es) * 2000-08-25 2004-09-10 Warner Lambert Co Proceso para la elaboracion del acido n-aril-antranilico y sus derivados.
US20020054869A1 (en) 2000-09-01 2002-05-09 Han-Mo Koo Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
AU2002255852B2 (en) * 2001-03-22 2006-11-09 Van Andel Research Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
IL149462A0 (en) * 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
EP1467968A1 (en) 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2478374C (en) 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005028426A1 (ja) 2003-09-19 2005-03-31 Chugai Seiyaku Kabushiki Kaisha 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
CN100594212C (zh) 2003-10-21 2010-03-17 沃纳-兰伯特公司 N-[(r)-2,3-二羟基-丙氧基]-3,4-二氟-2-(2-氟-4-碘苯基氨基)-苯甲酰胺的多晶型物
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
JP4869075B2 (ja) 2003-11-19 2012-02-01 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの複素環阻害剤及びその使用方法
BRPI0416852A (pt) 2003-11-21 2007-02-27 Array Biopharma Inc inibidores da quinase akt
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
JP2007530654A (ja) * 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
KR100889721B1 (ko) 2004-08-17 2009-03-23 에프. 호프만-라 로슈 아게 치환 히단토인
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
AR051248A1 (es) 2004-10-20 2007-01-03 Applied Research Systems Derivados de 3-arilamino piridina
US8022247B2 (en) 2005-04-06 2011-09-20 Chugai Seiyaku Kabushiki Kaisha Process for production of 2,3,4-trifluoro-5-(iodo or bromo)-benzoic acid
RU2500673C2 (ru) 2005-05-18 2013-12-10 Астразенека Аб Гетероциклические ингибиторы мек и способы их применения
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
EP2025347A4 (en) 2006-05-15 2010-08-11 Takeda Pharmaceutical PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
PL2049500T3 (pl) 2006-07-06 2012-02-29 Array Biopharma Inc Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
EP1908751A1 (en) * 2006-10-03 2008-04-09 EOS S.p.A. N-hydroxy benzamides with antitumour activity
KR20090071666A (ko) 2006-10-23 2009-07-01 다케다 야쿠힌 고교 가부시키가이샤 Ｍａｐｋ／ｅｒｋ 키나아제 억제제
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
JPWO2008075741A1 (ja) * 2006-12-20 2010-04-15 国立大学法人 長崎大学 糖尿病治療剤及び予防剤
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
EP2404907B1 (en) 2007-07-05 2015-01-14 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
BRPI0813999A2 (pt) 2007-07-05 2019-10-01 Array Biopharma Inc ciclopentanos de pirimidil como inibidores de akt proteína cinase
JP2010536723A (ja) 2007-08-16 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー 置換ヒダントイン
WO2009080523A1 (en) 2007-12-20 2009-07-02 F. Hoffmann-La Roche Ag Substituted hydantoins as mek kinase inhibitors
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
KR101624753B1 (ko) 2008-01-09 2016-05-26 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 저해물질로서의 수산화된 피리미딜 시클로펜탄
US8530457B2 (en) 2008-05-20 2013-09-10 Fox Chase Cancer Center Method for the treatment of lymphangioleiomyomatosis (LAM)
DK2307376T3 (en) 2008-08-04 2016-01-11 Merck Patent Gmbh NOVEL phenylamino ISONIKOTINAMIDFORBINDELSER
PA8840701A1 (es) 2008-08-27 2010-04-21 Leo Pharma As NUEVO RECEPTOR VEGF-2 e INHIBIDORES DE PROTEÍNAS TIROSINA QUINASA Y SU USO FARMACÉUTICO DE LOS MISMOS
WO2010051933A2 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CA2777071A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
AU2011224410B2 (en) 2010-03-09 2015-05-28 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US9045429B2 (en) 2010-10-29 2015-06-02 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
CN106893692B (zh) 2010-12-22 2021-11-26 菲特治疗公司 用于单细胞分选与增强ipsc重新编程的细胞培养平台
BR112013025397A2 (pt) 2011-04-01 2019-09-24 Deepak Sampath combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero
CA2831922C (en) 2011-04-01 2019-12-31 Genentech, Inc. Combinations of akt inhibitor compounds and vemurafenib, and methods of use
ES2597052T3 (es) 2011-05-25 2017-01-13 Université Paris Descartes Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
HRP20180670T1 (hr) 2012-10-12 2018-07-13 Exelixis Inc. Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
EP3094736A4 (en) 2014-01-14 2017-10-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
SG10201807292YA (en) 2014-03-04 2018-09-27 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
CN108473961B (zh) 2015-11-04 2022-11-29 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7194436B2 (ja) * 2016-07-28 2022-12-22 ザ ジョンズ ホプキンス ユニバーシティ Ｏ－置換ヒドロキサム酸
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
CN107556201B (zh) * 2017-09-08 2020-10-27 山西智创药研科技有限公司 一种制备间氨基苯酚的工艺方法
WO2020106305A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
JP7576799B2 (ja) * 2018-11-20 2024-11-01 エヌフレクション セラピューティクス インコーポレイテッド 皮膚癌の処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor

Also Published As

Publication number Publication date
AU757046B2 (en) 2003-01-30
CA2290506A1 (en) 1999-01-14
HUP0003731A3 (en) 2002-11-28
PT993439E (pt) 2004-12-31
WO1999001426A1 (en) 1999-01-14
DE69826662D1 (de) 2004-11-04
IL132840A (en) 2004-12-15
ATE277895T1 (de) 2004-10-15
BR9810366A (pt) 2000-08-29
NZ501276A (en) 2000-10-27
HUP0003731A2 (hu) 2001-04-28
CA2290506C (en) 2005-12-27
ES2229515T3 (es) 2005-04-16
KR20010014362A (ko) 2001-02-26
NO996491D0 (no) 1999-12-27
JP2002511092A (ja) 2002-04-09
NO996491L (no) 1999-12-29
CN1261877A (zh) 2000-08-02
HRP980368A2 (en) 1999-04-30
UY25076A1 (es) 1998-12-01
IL132840A0 (en) 2001-03-19
EP0993439B1 (en) 2004-09-29
IS5256A (is) 1999-11-19
DE69826662T2 (de) 2005-02-17
MY120994A (en) 2005-12-30
EP0993439A1 (en) 2000-04-19
ZA985728B (en) 1999-01-27
NO315271B1 (no) 2003-08-11
AR016762A1 (es) 2001-08-01
CO4940442A1 (es) 2000-07-24
TW396149B (en) 2000-07-01
CN1163475C (zh) 2004-08-25
PE97999A1 (es) 1999-11-05
AU8262798A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
PL337698A1 (en) Derivatives of 4-bromo- or iodo-phenylaminobenzhydroxamic acid and their application as mek inhibitors
PL331861A1 (en) Derivatives of propionic acid and their application
PL331047A1 (en) Novel amidinic derivatives and their application as inhibitors of thrombosin
PL338633A1 (en) Derivatives of aryloxyarylsuphonylamino hydroxamic acid
PL330482A1 (en) Novel amino acid derivatives and their application as thrombosin inhibitors
AU5493598A (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
EP1024130A4 (en) BIPHENYL-5-ALKANIC ACID DERIVATIVES AND THEIR USE
PL331895A1 (en) Arylosulphonylamino derivatives of hydroxamic acid
PL332324A1 (en) Derivatives of 4-heteroaroylpyrazole and their application as herbicides
AU7690794A (en) Acylpyrrole-alkanoic acids and indole-2-alkanoic acids plus their derivatives for use as inhibitors of phospholipase a2
PL333505A1 (en) Benzamido-aldehydes and their application as inhibitors of cysteinic proteases
FI973974L (fi) Aryylisulfonyylihydroksaamihappojohdannaisia MMP- ja TNF-inhibiittoreina
HU9700602D0 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
PL344589A1 (en) COMPOSITION COMPRISING β-HYDROXY-β-METHYLBUTYRIC ACID AND AT LEAST ONE AMINO ACID AND METHODS OF USE
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
AU5886296A (en) Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
ZA989064B (en) Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
PL342500A1 (en) Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists
PL340461A1 (en) Derivatives of isothiazocarboxylic acid
GB9507415D0 (en) Production and uses of caffeic acid and derivatives thereof
PL333112A1 (en) Substitute derivatives of 4-biphenyl-4-hydroxybutyric acid as inhibitors of matrix metaloproteases
PL341221A1 (en) Derivatives of phenylaminoalkyl carboxylic acid and pharmacological compositions containing them
IL114439A0 (en) Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis